AMSURG Medical Director Dr. Bergein Overholt Work with ColoMarker Accepted for Presentation at 2014 ASCO

amsurg_logo.gif

AMSURG physician Bergein Overholt, M.D., medical director for The Endoscopy Center in Knoxville, Tenn., is the lead author for the abstract presenting an analysis of the biomarker called ColoMarker (patent pending). The abstract has been accepted for presentation at the 2014 American Society of Clinical Oncology meeting in Chicago being held on May 30 – June 3.   The ColoMarker was developed by EDP Biotech Corporation, an in-virto cancer diagnostics company. The ColoMarker is a serologic tumor marker for colorectal cancer that correctly identified 100 percent of 63 patients with Stage I-II colon cancers. The test remains experimental.   Full Story